Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands				1 Months Ended			6 Months Ended		12 Months Ended
	Dec. 03, 2021	May 17, 2021	Mar. 10, 2021	Nov. 30, 2021	Oct. 31, 2021	Feb. 28, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Nov. 17, 2021
Business Combinations [Line Items]
Long-term notes receivable—related parties							$ 7,040		$ 3,835
Research and Development in Process							$ 357	$ 8,934
Equity Method Investment, Ownership Percentage							80.00%		80.00%
Chymia, LLC [Member]
Business Combinations [Line Items]
Long-term notes receivable—related parties							$ 100
PsyProtix Purchase Agreement [Member]
Business Combinations [Line Items]
Cash consideration, net of cash acquired						$ 100
Estimated fair value of contingent consideration						$ 4,900
Number of days of voting and other rights of expiration date						10 days
Company's capital contribution threshold limit						$ 5,000
Loan received						$ 100
Interest rate						5.00%
Aggregate principal amount						$ 100
Business Combination, consideration paid									$ 100
Business Combination, identifiable assets acquired									100
Business Combination, clinical milestones payment amount					$ 500
PsyProtix Purchase Agreement [Member] | Series A Preferred Stock [Member]
Business Combinations [Line Items]
Preferred Stock Restated shares					500,000
PsyProtix Purchase Agreement [Member] | PsyProtix, Inc. [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests						75.00%
PsyProtix Purchase Agreement [Member] | Chymia, LLC [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests						25.00%
Psyber Purchase Agreement [Member]
Business Combinations [Line Items]
Cash consideration, net of cash acquired						$ 200
Estimated fair value of contingent consideration						$ 1,800
Number of days of voting and other rights of expiration date						10 days
Company's capital contribution threshold limit						$ 2,000
Business Combination, consideration paid									200
Business Combination, identifiable assets acquired									200
Psyber Purchase Agreement [Member] | Psyber, Inc. [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests						75.00%
Psyber Purchase Agreement [Member] | Psyber, LLC [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests						25.00%
InnarisBio Purchase Agreement [Member]
Business Combinations [Line Items]
Cash consideration, net of cash acquired						$ 1,100
Estimated fair value of contingent consideration						$ 3,900
Number of days of voting and other rights of expiration date						10 days
Business Combination, consideration paid									1,100
Business Combination, identifiable assets acquired									2,000
Business Combination, fair value of the noncontrolling interest issued									900
Purchase consideration for the noncontrolling interest and recognized as a liability									100
Business Combination, clinical milestones payment amount				$ 1,200
Research and Development in Process									$ 1,000
InnarisBio Purchase Agreement [Member] | Series A Preferred Stock [Member]
Business Combinations [Line Items]
Preferred Stock Restated shares				1,238,000
InnarisBio Purchase Agreement [Member] | InnarisBio, Inc. [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests						82.00%
InnarisBio Purchase Agreement [Member] | UniQuest, LLC [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests						18.00%
Neuronasal, Inc. [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests		56.50%
Neuronasal, Inc. [Member] | Series A Preferred Stock [Member]
Business Combinations [Line Items]
Business Combination, purchase of shares		$ 1,000	$ 800
Neuronasal, Inc. [Member] | Common Stock [Member]
Business Combinations [Line Items]
Business Combination, purchase of shares			$ 300
TryptageniX, Inc [Member]
Business Combinations [Line Items]
Estimated fair value of contingent consideration	$ 900
Business Combination, consideration paid	1,000
Business Combination, identifiable assets acquired	6,500
Business Combination, fair value of the noncontrolling interest issued	3,900
Equity Method Investment, Ownership Percentage										65.00%
Fair value of liability for seller financing	800
Business Combination, IPR&D asset	6,500
Exclusivity fee, Additional payment	1,000
Exclusivity fee, First Installment	2,000
Exclusivity fee, Remaining installment	$ 1,000
TryptageniX, Inc [Member] | Common Class A [Member]
Business Combinations [Line Items]
Held in escrow										$ 2,000
TryptageniX, Inc [Member] | CBT holding [Member]
Business Combinations [Line Items]
Equity Method Investment, Ownership Percentage										35.00%